share_log

Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8

Moomoo 24/7 ·  Mar 6 07:38

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and lowers the price target from $10 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment